University of Pennslyvania
Health Systems
Office of Public Affairs
399 South 34th Street, Suite 2002, Penn Tower, Philadelphia,
PA 19104-5653
Contact:
Jen Miller, (215) 349-5657, jennifer.miller@uphs.upenn.edu
November 25, 2003
Physicians Should Prescribe Cholesterol-lowering Medicines More to Select Patients
While Still Hospitalized
Study finds that this could improve quality of life for patients with cardiovascular diseases
(Philadelphia, PA) - Although cholesterol-lowering agents have been shown to
dramatically reduce the likelihood of cardiovascular diseases, few people who
qualify for these drugs actually receive them. A study published in the current
issue of Archives of Internal Medicine suggests that increasing the appropriate
use of cholesterol-lowering therapies – while the patients are still in
the hospital – could translate into improved clinical outcomes.
Herbert Aronow, MD, MPH, Assistant Professor of Medicine at
the University of Pennsylvania School of Medicine, and researchers
at the Cleveland Clinic studied more than 2,100 patients at nearly 70 United
States and Canadian hospitals undergoing heart angioplasty in the EPILOG trial.
The researchers asked the question: ‘If patients with cardiovascular disease
are hospitalized, does it matter whether cholesterol-lowering agents are begun
before discharge or whether that decision is deferred to the outpatient setting?’
They found two things: first, patients who started the medicine while in the
hospital fared better than those who didn’t; and second, those patients
who started the medications while in the hospital were more likely to continue
using the drugs following discharge.
“The bottom line is that we need to capitalize on the opportunity to initiate
these life-saving medications in the hospital when our patients are most motivated
to alter their lifestyle or medical regimens,” said Aronow.
“The findings were remarkable,” he continued. “Patients who
were started on cholesterol-lowering agents while hospitalized were nearly three
times more likely to be taking these medications in follow-up than those who
went home without them. Given the well-established benefits associated with
cholesterol-lowering drugs and the high prevalence of cardiovascular disease,
any strategy that leads to increased drug utilization could have a tremendous
impact on our societal health.”
Atherosclerosis, the build-up of fatty deposits (‘plaque’) inside
the body’s arteries is the leading cause of death and disability worldwide.
This disease is responsible for most heart attacks and strokes and ultimately
leads millions of patients worldwide to undergo heart angioplasty and bypass
surgery each year.
“Cholesterol-lowering agents, such as statins, reduce the chances of dying,
having a heart attack or stroke or needing angioplasty or bypass surgery by
roughly one third,” said Aronow. “Nevertheless, recent surveys revealed
that only one to two-thirds of eligible patients are prescribed these medications.
Further, among those taking these medications, most are on too low a dosage
to be clinically effective.”
He also cautioned that, “despite the substantial health benefits attributed
to these medications, they are no substitute for a healthy lifestyle. Diet,
exercise and smoking cessation are the cornerstones of prevention and should
be considered as complementary to, not in place of, medical therapy.”
# # #
PENN Medicine is a $2.2 billion enterprise dedicated to the related missions
of medical education, biomedical research, and high-quality patient care. PENN
Medicine consists of the University of Pennsylvania School of Medicine (founded
in 1765 as the nation’s first medical school) and the University of Pennsylvania
Health System (created in 1993 as the nation’s first integrated academic
health system).
Penn’s School of Medicine is ranked #2 in the nation for receipt of NIH
research funds; and ranked #4 in the nation in U.S. News & World Report’s
most recent ranking of top research-oriented medical schools. Supporting 1,400
fulltime faculty and 700 students, the School of Medicine is recognized worldwide
for its superior education and training of the next generation of physician-scientists
and leaders of academic medicine.
Penn Health System consists of four hospitals (including its flagship Hospital
of the University of Pennsylvania, consistently rated one of the nation’s
“Honor Roll” hospitals by U.S. News & World Report), a faculty
practice plan, a primary-care provider network, three multispecialty satellite
facilities, and home health care and hospice.
Release available online at http://www.uphs.upenn.edu/news/News_Releases/nov03/aronow.htm